Pod Insights Pharmacy Podcast Network The Peptide Problem | Essential: The Pharmacy Compounding Podcast About this episode In this edition of Essential, we’ve got concerns about the FDA’s revolving door, some issues with a new California law that might affects the whole country, and a new accreditation that might save a lot of headache. Then we take a deep dive into the once and future world of compounded peptides — where they are, and where they might be going … and why. LinksFDA’s revolving door: https://archive.ph/oxBXP Join APC today: https://a4pc.org/membership Coalition for Compounding Excellence (CCE) accreditation: https://414uue.share-na2.hsforms.com/2n_hRAnRSQ4O8VteGTesF0Q?_hsenc=p2ANqtz-9rfyq3GuFFZw6omRa96tq_es549FWmjiw-sP5NU3LKrsL1eump-l18h7xVrvy8G_V1Pi4UFkfhARMnPCLIx7TBOwPClQ&_hsmi=394109070Pharma Source Direct: https://www.linkedin.com/company/pharma-source-direct/
Transcript 0:05 Speaker 00 You are listening to the global network of podcasters dedicated to the pharmacy profession. Welcome to the Pharmacy Podcast Network.
0:27 Speaker 01 Welcome back to Essential, the pharmacy compounding podcast with the latest news and analysis from you know it, the Alliance for Pharmacy Compounding, the voice for compounding pharmacy. I'm your host, Andrew Cantor, and after the news today, we've got peptides, like everything you need to know about them, what they are, why people are so interested in them, and from a compounding point of view, what's happening with them. But first, let's do a few bits of pharmacy compounding news.
1:02 Speaker 01 There's a great op-ed in Stat News you ought to check out. It's all about the revolving door at the FDA. And by that, we mean how it seems that a lot of FDA officials are leaving the agency and then going to work for the companies they were just supposed to be regulating. In one case, an official in the FDA's compounding division was, what's the phrase, reduced in force, laid off. Anyway, she went to work as a lobbyist for a GLP-1 drug maker, where suddenly she became quite anti-compounding, not surprisingly. The thing is, federal law prohibits ex-government employees from representing private parties in the issues they worked on while working for the government. It's a lifetime ban,
1:45 Speaker 01 but laws are only laws if they're actually enforced. Cases like that are why the authors of the Stat News column, that's Lee Rosebush, who's chairman of the Outsourcing Facilities Association, and pharmacist attorney Mac Wagner, they say it's kind of hard to have a lot of respect or trust in an agency when you think people there are just auditioning for a spot with a private company. The interesting thing is, Rosebush and Wagner have a plan. Check it out. The link to the article and the column is in the show notes.
2:17 Speaker 01 In California, the Board of Pharmacy there is proposing a rule that would require central fill pharmacies not only to be licensed in California, but operate within California. So, non-resident pharmacies wouldn't be allowed to act as central fill providers. You can see why this would be a problem. With our friends at NCPA, we reached out to the Board of Pharmacy there to formally oppose the rule, but also to suggest a simple alternative. Bay law already puts requirements on non-resident pharmacies that dispense in California. So, why not just apply those same requirements to central fill pharmacies? It's a lot simpler, and honestly, a lot better for patients.
2:57 Speaker 01 But then again, this is the California Board of Pharmacy, which seldom tells us why. There's a little problem in Illinois that's really about, I guess it's kind of a bit of government inefficiency. There's a new law there that requires out-of-state pharmacies that want to dispense into Illinois to have a pharmacist in charge who's licensed in the state. Makes perfect sense. The problem is that the law takes effect on January 1st, 2026. But even pharmacists who have put in their application for Illinois licenses months ago, they haven't heard back. We're hoping the state won't jump into enforcing the new law right away. We and NCPA have asked the Illinois Board for a bit of enforcement discretion.
3:41 Speaker 01 Give the state time to process those licensed applications without punishing the pharmacists who are trying to follow the law. Ah, accreditation. The best part of the job for any pharmacy owner. And yes, that was sarcasm. We know how big a hassle it is. Plus, the frustration knowing that there's so much overlap, plus the whole mix of deadlines, and this huge time sink. APC is run by pharmacists, you know, and a lot of our members are pharmacy owners. So, yeah, they're dealing with the same thing, and that is why we have come up with something better. It's a new accreditation from the Coalition for Compounding Excellence, or CCE, and it's got some teeth.
4:23 Speaker 01 The idea is to make your life easier by cutting down on hassle. CCE accreditation ticks all the boxes. There's USP adherence, facilities, equipment, personnel, processes, basically the whole gamut of what today's regulations are expecting. It means you can spend less time dealing with the fun paperwork of a stack of accreditations, and more time, you know, helping your patients. One big thing CCE focuses on, and this is something pharmacy owners can appreciate, is multi-state licensure. Why deal with separate evaluations for every state you want to dispense to when CCE can do that in one visit? Bet that got your attention. How about this? CCE's inspectors are actually pharmacists compounding pharmacists. They know what's
5:08 Speaker 01 what. They get the reality of your back room. And, and this is important, they're not just looking to find problems. They want to help you resolve them. The whole idea is to make your life easier, remember? All right. Obviously, this sounds good, but, and you know there's a but, CCE accreditation is only available for APC members. In fact, APC pharmacy facility members get a pretty big discount, like up to half the price of other accreditation programs. So if you're an APC member and you own a pharmacy, you probably want to check this out. There is a link in the show notes. And if you're not an APC member, well, this is just another reason you ought to be.
5:48 Speaker 01 And now it is on to this episode's deep dive. There's a lot of talk out there about peptides. If you believe what you see on TikTok, which you shouldn't always, peptides are the cure for everything from bad breath to osteoporosis. But in the real world, there are a lot of restrictions on working with peptides. There are a lot of rules and honestly, a bit of confusion. So here today, we've got a couple of folks to talk the peptide talk, what they are, how they work, what's happening with regulation, and what looks like it may be coming down the pike. This will be a pretty geeky discussion, no offense to our experts, so get ready. You know Tenille Davis. She's APC's Chief Advocacy Officer, and she's also
6:31 Speaker 01 a longtime pharmacist with a boatload of regulatory experience, including attending the pharmacy compounding advisory committee meetings when they talked about peptides. Like a lot of you, she is well aware that prescribers and patients really, really want access to compounded peptide therapies. And Matt Johnson, he's President of Farm Source Direct. It's an FDA-registered API wholesaler. He's got years of experience as a supplier to compounding pharmacies, and he is also a member of APC's Board of Directors. Welcome to the podcast, both of you. So why don't we start at the very beginning, a very good place to start. Tell us what peptides actually are, and why there's all this interest these days in using them as treatments.
7:16 Speaker 02 Sure, thanks Andrew. Peptides are, you know, short chains of amino acids. They act in our body as a signaling hormone to tell our body to do lots of things. But when we hear about peptides on TikTok or on Instagram or in the news, we're hearing about peptides as certain category of peptides. Those are ones like BPC157, CJC, kisspeptin, ipamorulin. So even though there's a lot of peptide drugs that are FDA approved that are used to treat patients now, that when you hear the word peptides in the, you know, the online being advertised to you,
7:55 Speaker 02 they're really talking about this certain group of anti-aging peptides like BPC157. Matt, so these are chains of amino acids. Can you explain the difference between an amino acid and a protein? And what the cutoff is for the amino acid length that makes peptides peptides and proteins biologics and drug categorization?
8:21 Speaker 03 Yeah, certainly. I think this definition became more prevalent about six years ago when FDA reclassified HCG. At that point in time, they defined the difference between a biologic and a peptide as 40 branched-chain amino acids or less. So anything above the 40 branched-chain amino acids would be considered a biologic. Anything below that is going to be considered a peptide. I think the primary difference is going to be when synthesizing the material, it is made either from recombinant material or completely synthesized through the pharmaceutical process.
9:01 Speaker 02 Yeah, in the last 10 years, there's been a lot of advancement in the manufacturing processes for peptide drugs. It used to be that all manufacturing was done via the recombinant technology, which is basically training a type of bacteria to produce chains of amino acids in a certain sequence. But now pharmaceutical companies have the ability to do all of that synthetically. FDA doesn't differentiate between recombinant and synthetic manufacturing processes when there's a drug that is getting approval as a new generic. So if the brand name product was synthesized via recombinant technology, but the new generic
9:42 Speaker 02 that's looking for abbreviated new drug approval is done by a synthetic, the FDA, as long as the API is the same at the end, the FDA doesn't differentiate between those two manufacturing processes. And the synthetic process is a lot easier. So there's been a big boom in peptide manufacturing over the last 10 years and a lot of interest in peptides.
10:05 Speaker 03 Ultimately, as long as the molecular structure, as you indicated, remains the same, then it will be considered similar or same to whatever was approved through the recombinant process. And that's what we're seeing is the majority of manufacturers are now releasing the synthetic versions of these recombinant molecules that do follow the same molecular structure. They have the same optical rotation, they have the same molecular weight, and they have the same branch of amino acids making up that unique peptide.
10:36 Speaker 02 So I'm going to talk about this group of peptides. So right here, we're not talking about the kind of peptides that you all know and love like oxytocin or vasopressin. We're talking about this kind of anti-aging group of peptides. But prior to 2023, these peptides were available more often because the FDA had yet to take action to formally categorize them on one of its bulk lists for compounding. Even though before 2023, these peptides like BPC157 didn't meet the criteria for compounding at the time. Matt, can you explain what three criteria an API has to meet in order to be used in a compounded product?
11:20 Speaker 03 Yes, presently, the criteria to meet a human compounded product would be that it has to either have a USP monograph, it has to be a component of an approved human drug, or it has to appear on the bulk's list, otherwise known as List 1.
11:36 Speaker 02 Yeah, so these peptides never appeared on the List 1. But in 2023, in the fall, the FDA quietly moved a big group of these peptides to List 2. In the interim List 2, those are the API that are not allowed to be used in a compounded product. A lot of people thought the FDA violated the Administrative Procedures Act because they did this without notice and comment rulemaking, and they were subsequently sued by a group of interested parties. That lawsuit was eventually settled, and the FDA conceded that it needed to go through the Pharmacy Compounding Advisory Committee process review for some of these peptides.
12:21 Speaker 02 So in late 2024, the FDA held PCCAC, or Pharmacy Compounding Advisory Committee, meetings to evaluate four of this more than a dozen peptides. The outcome of those advisory committee meetings is that the FDA recommended that these peptides not be placed on List 1 or the interim list that allows compounders to use these products in compounding. So it caused a lot of, you know, kind of rage in the wellness industry because there's a lot of interest in these kind of peptide drugs, and now they became officially off limits for compounding.
13:04 Speaker 02 So even though they didn't meet the criteria before, no one had come out and say that these are absolutely against the rules until this PCCAC meeting and them placing them on List 2.
13:16 Speaker 03 Yeah, that's correct. And I think one of the biggest challenges for compounding pharmacies is that they were successfully utilizing these peptides for a significant amount of time and had limited reported adverse reactions at that time. So the pharmacists were kind of blindsided by this as it was a large part of their business models. The patients were also really requesting refills on these items because they were relying on these prescriptions for a significant amount of time, and then they were immediately yanked away from these patients. So at the end of the day, the patients were the ones that were suffering from the result of this decision.
13:57 Speaker 02 Yeah, and so the outcome now is that it's forced all the people interested in using these kinds of medications down the research use pathway. So instead of getting these medications filled by legitimate state licensed compounding pharmacies that have all sorts of standards that they have to follow, now patients are able to order these kind of peptide drugs online over TikTok without a prescription at all. And there's no guarantee that what the patient is receiving in the mail contains what it's purported to contain at all. So in essence, it's this action by the FDA has made the peptide industry less safe.
14:38 Speaker 03 Yeah, I couldn't agree more. Unfortunately, patients are going to find whatever it is that they're looking for and they turn to sources that they assume to trust, but they don't really have the regulatory purview or perspective on what's good, what's bad. A website is out there selling them on what they need to hear and how they need to hear it. But the reality is, and through some significant research in communicating with a lot of these manufacturers, to prepare GMP and pharmaceutical grade material, it doesn't exist right now. The majority of the material is either dietary supplement grade or it is research and development grade. It's not for human use. And that leads to a lot of risk for these patients. They don't know what they're getting.
15:23 Speaker 03 They don't know how it was made. They don't even know the potency of the products that they are receiving. Whereas at a compounding pharmacy, especially in a sterile environment, the pharmacies are going to be beholden to the regulations that oversee their practice to ensure sterility, to ensure potency, to ensure that the identity of the material that they're receiving is truly what they were receiving. So at that point in time, there's been a huge uprising of pharmacies that are lobbying to bring a number of these peptides back on the approved list so that they can prevent patient harm, so that they can educate patients. And I think that obviously APC does a good job trying to educate patients on where to
16:06 Speaker 03 find, or not necessarily where to find, but criteria associated with what would be safe and effective use of drugs. And because there's no real legal definitions of how to utilize these, it's difficult to comment, it's difficult to guide on these. The only guidance we really have is through the GMP, through good manufacturing practices. And as I indicated before, with the dietary supplement grade material that exists out there in the market right now, that follows a completely different set of standards. Those standards do not achieve the same safety aspects that a pharmaceutically, pharmaceutical grade manufactured item would
16:46 Speaker 03 meet. So what we've done is we've been anticipating some movement within the government to bring the allowance of some of these peptides back into the eligibility for compounding. In doing so, we've been communicating with a number of manufacturers to convert these from their R and D grade material into a pharmaceutical grade material. And it's not as turnkey or as easy as one would suspect. There's a lot of method validation and method development, testing, and ultimately verifying that what they're doing can still meet the standards, can still be safe by the regulations that are set forth, and in continue to ensure
17:28 Speaker 03 that what patients will ultimately receive is going to be suitable for what they're expecting.
17:34 Speaker 02 Yeah, Matt, the industry argues that the pharmacy compounding advisory committee didn't give these peptide drugs a fair shake, and that the process itself needs to be overhauled. So how this meeting worked, where they evaluated these peptides and determined not to include them on list one, the FDA has, you know, unlimited time to make a presentation to the pharmacy compounding. Advisory Committee about its concerns with these certain peptide drugs. But industry only has a limited amount of time to respond. So even if there's multiple people wanting to comment to the advisory committee, they have to share that amount of time. I think it was limited to about 10 minutes worth of presentation time.
18:17 Speaker 02 And the FDA can talk for as long as they want to try to convince the advisory committee to not include these substances on the interim list one. We also have concerns over the makeup of the pharmacy compound named Advisory Committee. So, you know, obviously, they're all smart people, but a lot of them exist in academia. They've never practiced with this group of, you know, treating patients or using these kind of therapies, seeing these kind of drugs in action. So we're looking for an overhaul of the whole process and an overhaul of the makeup of the advisory committee, and it looks promising. So what you were saying earlier about kind of movement within the industry, it looks like the advisory committee right now has six openings.
18:58 Speaker 02 So we're hoping that this new administration, this new HHS nominates some kind of new faces into that role so these substances can be reevaluated by the committee.
19:10 Speaker 03 Yeah, and if I could comment on that too, Tanja. From what I recall, at the time of that PCAT committee, there were no compounding voting members that sat on that committee and which they're the ones with the expertise, they're the ones with the experience, and they weren't even given the opportunity to vote yea or nay. They are given a voice to a certain aspect, but without being too biased, I've sat in on a number of these meetings, and what I've seen is that the presenters do a tremendous job providing information that indicates suitability of the materials that they're presenting. But it always appears as if the committee has already come into the meeting with their answers and their decisions already made, and no matter how good the presentations
19:55 Speaker 03 are, it appears that they're going to be denied. There's been very few cases in which I've seen a legitimate argument has made it through or that the committee has already made a decision ahead of time that was positive for the compounding industry. But these experts that are submitting these and nominating these drugs spend an incredible amount of time researching, trying to find a balanced presentation on adverse events versus positive patient outcomes so that they can receive an unbiased vote on these. And unfortunately, we've just seen the outcome. On the negative side of that. And so, yes, as you indicated with these six open seats, the hope is that we get some legitimate practitioners that can sit on this board,
20:36 Speaker 03 help to educate the academia members as well, and get more of a fair trial, so to speak.
20:42 Speaker 02 Yeah, you're exactly right. So, moving forward, you know, where is the industry gonna go? I don't know if you all saw, but there was kind of a really viral tweet that Robert F. Kennedy Jr. made at the beginning of the administration about bringing back certain therapies, and he specifically called out peptides. There have been multiple letters written by members of Congress to the FDA asking for some sort of movement in this peptide space. So enforcement discretion to allow compounders to compound with these peptides while they're being reevaluated by a new and improved pharmacy compounding advisory committee process. We've heard whispers
21:25 Speaker 02 and rumors through the industry that there's something forthcoming from the FDA that is going to make these peptides available for use in compounding. And we're all, you know, we're all excited about that. One of APC's kind of big asks at the beginning of this administration in our blueprint document was that PCAP review these kind of substances for use in compounding with a kind of a different lens than they have in the past. Because compounded medications and the API like this that are not part of FDA-approved products do not have USP monographs, they don't have large-scale, double-blind, placebo-controlled trials. So the FDA can't really evaluate them for safety and effectiveness the same
22:06 Speaker 02 way they are able to evaluate drugs that are submitted for formal FDA approval. We're asking for the FDA to kind of change the perspective and look for demonstrable safety risks, and if those can't be proven, to not require effectiveness data in order to allow these compounds to be used, or these API to be used in compounds. That way pharmacies can start treating these patients. These doctors are asking for these medications to be available for use in their patients. It's something that is so... Wanted out there in the industry. As someone who worked in a compounding pharmacy, I can tell you that it felt like some days every other phone call was someone asking if we made these kind of medications at my pharmacy. And we're really looking forward
22:49 Speaker 02 to things changing. So what next? If the FDA does announce a period of enforcement discretion, Matt, you are a wholesaler, so you source API from FDA-registered manufacturers. How would you go about trying to source API that would be appropriate for use in, say, a sterile compounded product when there is no API-grade materials out there yet because these are not currently authorized for use?
23:17 Speaker 03 Well, it's a great question, and I want to compliment you on your summary of what is occurring right now, because I think it's very apt. I think that this new administration and this Maha movement is taking a different approach than what we've seen in the past, or a little bit more sympathetic and open-eared to some of the experts that live within this industry that do have significant evidence that can suggest that these are legitimate therapies and that they should be utilized more. You know, I first heard about, and a lot of this was all hearsay, most of it is hearsay until it becomes published, but we heard that they were going to release a list in November, and then it was December. Originally, I actually heard February, and that's what I've been planning for and really
24:01 Speaker 03 hoping that we have that amount of time to convert everybody, or individuals or individual manufacturers who are willing to participate in this. Obviously, the GLPs are where we begin. That's how we're going to find these sources. Normally, what we would do is look for FDA-registered manufacturers who also have registered NDCs for particular APIs. In this case, it's very difficult, because since they're not currently prescription drugs, at least not categorized by the regulatory bodies. Legally, they should not have registered NDC numbers listed on those. And for folks who are listening who don't understand what an NDC is, it's a national drug code. The national drug code is registered by every manufacturer to identify
24:45 Speaker 03 through segments of an NDC. The first segment identifies, it's a code that identifies the original manufacturer. The second set of numbers in an NDC code identifies the specific product produced by that manufacturer. And the third set of numbers identifies the package size. There's a databank on the federal website that identifies folks who have these numbers registered. So normally, we would start there. We want to start with folks who are already manufacturing this material, that already have them registered appropriately, and also allows us to investigate these manufacturers to determine, when was their last FDA inspection? What is the risk associated with these manufacturers? Any firm can register with the FDA. FDA does not issue licensing.
25:26 Speaker 03 FDA does not inspect your facility before issuing the registration. So the concern is, how many of these folks have recently registered based on the GLP-1 craze that was taking the world, and especially the country by storm? And how many of these are legitimate? Well, that's where the wholesalers come in. It's our job to go in. We do an initial paper audit to ensure that they're following GMP. We audit their products to also ensure that those products are following the appropriate processes to enter into the public market. And ultimately, we want to get on site. We want to see if they look as good in person as they do on paper. What we're finding right now is that a number of these manufacturers
26:09 Speaker 03 have either recently entered the market, they're not familiar with the documentation we're requesting, which ironically, the documentation we're requesting is in the federal guidelines. Or we're being told, well, other people that we're selling to are not requesting this information, why are you? We explain to them that this is the regulatory process. If they want to sell legally inside the United States, this is the process they have to follow.
26:33 Speaker 02 This is a great time to bring up the fact that APC is releasing a new best practices document to help pharmacies with this very issue, Matt. So It's a best practices for vendor validation. It helps pharmacies with the tools that they need to determine if the vendors that they're working with to order things like API are following all the steps that they need. So they're getting a product that meets all the specifications. They have all the correct licensing and registration. They've got the inspection reports, 483s, anything they might need to evaluate it. So I just wanted to put a little plug there for our vendor validation best practices. So if they do order API or they are looking to order API in this peptide space for these peptides that may have enforcement discretion.
27:19 Speaker 02 Can you go over just very briefly some of the things on a C of A pharmacy might look for to determine if that could be appropriate for use in compounding?
27:28 Speaker 03 Yes, absolutely. And I'm glad you brought up that best practice form. I've had the opportunity to review it. I think it's very well put together. And I think it's guidance that has absolutely been needed for a long time. Pharmacists follow USP. They don't know what they don't know in terms of some of these certificates of analysis. And one big distinction here is that peptides, because they do not have a USP monograph, we have to go based on manufacturer standards and manufacturer criteria. That can create risk because some manufacturers might not want to analyze these APIs to the extent to which would be intended to ensure safety. But fortunately, the USP has identified at minimum certain criteria that needs to appear on a certificate of analysis.
28:14 Speaker 03 Obviously, the name is one of those so that we can be able to identify that product specifically. The manufacturer's information as well, so that we can track and trace the manufacturer and determine that they're FDA registered. But more so, you have your assay. You have your peptide purity. You have your water content. You have your elemental impurities. And you also have your residual solvents. At minimum, those have to appear on a certificate of analysis or it's not a valid certificate of analysis, whether it be an item that has a monograph or if it's a non-monographed item. I think a lot of pharmacists. They are more concerned with what they're going to be utilizing in their formulations, and they'll look at the purity so that they can count the purity or the water content
28:58 Speaker 03 so that they can formulate their prescription. And if those results test within the criteria or the specifications assigned on that C of A, they're going to assume everything is on the up and up and that the quality is good. But ultimately, it has to have this other criteria, and I have seen some C of As that were so nominal that we just had to kick them back and immediately disqualify these manufacturers. We've gone to great lengths to have conversations and educate these manufacturers, but at the end of the day, it's not our job to educate these manufacturers. These manufacturers are beholden to these requirements, and they should be providing this information upfront without a significant number of questions or concerns associated with the documentation that they present.
29:41 Speaker 03 So I think it's incredibly important that, you know, you don't just measure the results of these specifications, that you understand what these ranges are. So for example, in most cases, APIs have a test range of 98 to 102% for purity. That's different than pharmacies. When pharmacies send out their prescriptions, typically they have a threshold of 90 to 110% on their purity range because they're dealing with excipients and other elements put into that formulation. When you're dealing with 100% pure material, you get these ranges, and typically it's only a limitation based on the equipment that's being used to analyze these materials.
30:24 Speaker 03 At the end of the day, we wanted to measure it 100% pure. Or 100% pure minus any unspecified impurities or any residual solvents that might be components or byproducts of the manufacturing process. And those are allowed. But without the understanding of that, you're going to look at something, and even if they have a criteria that's 92 to 118, they're going to say, well, it fell in it at 93%, so it's good, right? It tested within the range. And that's just not it. It's, we have to educate further and ensure the integrity of these products that are going to be entering the marketplace.
31:00 Speaker 02 I would like to point out that FDA-approved products also have a potency range of 90 to 110%, not just compounded products. That is what is legally required for both FDA-approved drugs, finished drugs, and compounded products. So with peptides, we know these are powerful medicines and that there's a lot of interest from the public in having access to these medications. And we really, really are pushing for legitimate state-licensed compounding pharmacies to be able to be the ones to fill that role, rather than patients ordering these things from who knows where, online, using research-grade products that are manufactured under unknown
31:43 Speaker 02 conditions and contain unknown, you know, final products. But as of right now, they don't currently meet the criteria for compounding. So APC's job is to educate compounding pharmacists what they are allowed to do and what they're not allowed to do. So we wait with bated breath for some sort of announcement from the FDA that these are going to be made available. But as of right now, we still have to wait for that announcement to come. I think that's probably all we need to talk about peptides. So Andrew, if you want to close us out, we can say goodbye.
32:16 Speaker 01 Well, thank you both, Tanil and Matt. Thanks for coming here, sharing really the kind of expertise we don't get enough of. And based on what you've been saying, it feels like we're on the cusp of something big happening on the peptide front, or at least with some peptides. So I can totally see us coming back here in a couple of months, a few months, with a major update. Maybe not, we don't know. Obviously, we'll be keeping an eye on the entire issue, and we'll be keeping our members in the loop.
32:49 Speaker 01 All right, that is it for this episode of Essential. But before we play the end music, something I want to point out. If you are a compounding pharmacist, or a technician, or you prescribe compounded meds, APC is almost certainly helping you, and helping your patients, and helping your practice and your business. I'm not going to go through everything we do, but I will say that APC is the biggest, and in a good way, the loudest trade association for the whole compounding profession. If you're not a member of APC, you really ought to be. We're working for you and we'd love to have you on board. Head over to A4, that's the number four, pc.org. A4pc.org. Check us out.
33:34 Speaker 01 And now we can play the end music. Thanks for listening.
Previous From Counter to Clinic: Implementing Prescribing Services | Pharmacist-Prescribed Next Doing Things Differently: YARAL Pharma, Pennsylvania Policy, and the Birth Control Pharmacist | TWIRx Page updated November 14, 2026 · transcript and summary are machine-generated